Nascent Biotech Inc. (NBIO)

[BlazingStocks]

I foresee 2 PRs in the near future...on Phase I and Phase II. We're early but with a great opportunity to load cheaper shares from the impatient.

The review is required for approval to commence the next phase in the development of Pritumumab ("PTB"). Data related to Phase 1 Clinical Research evaluating safety and tolerance for PTB as a treatment for Primary and Metastatic Brain Cancers has also been submitted to the FDA.

$NBIO